Abbott has received CE mark approval for its XIENCE PRIME and the XIENCE V Everolimus Eluting coronary stent systems.
The approval of stent systems was based on the use of dual anti-platelet therapy (DAPT) for at least three months after stent implantation in patients with coronary artery disease.
Abbott Vascular chief medical officer and medical affairs divisional vice president Charles Simonton said with the new indication, physicians can have confidence in being able to safely discontinue DAPT after a minimum of three months for patients who were treated with a XIENCE stent systems.
"Clinical data from more than 10,000 patients show that XIENCE is associated with similar safety results in patients who interrupted their DAPT medication after three months compared to patients who never interrupted their medication," Simonton added.
"Reducing the amount of time patients need to remain on DAPT can have a significant impact on patient health and may lead to decreased health care costs."
XIENCE PRIME and XIENCE V are indicated for improving coronary artery luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions of less than or equal to 32 mm and 28 mm respectively.